169 related articles for article (PubMed ID: 22918118)
1. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype.
da Silva Rocha LB; Dias Elias DB; Barbosa MC; Bandeira IC; Gonçalves RP
Mutat Res; 2012 Dec; 749(1-2):48-52. PubMed ID: 22918118
[TBL] [Abstract][Full Text] [Related]
2. Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.
Bandeira IC; Rocha LB; Barbosa MC; Elias DB; Querioz JA; Freitas MV; Gonçalves RP
Cytokine; 2014 Feb; 65(2):217-21. PubMed ID: 24290434
[TBL] [Abstract][Full Text] [Related]
3. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
[TBL] [Abstract][Full Text] [Related]
4. Inheritance of the Bantu/Benin haplotype causes less severe hemolytic and oxidative stress in sickle cell anemia patients treated with hydroxycarbamide.
Okumura JV; Silva DG; Torres LS; Belini-Junior E; Barberino WM; Oliveira RG; Carrocini GC; Gelaleti GB; Lobo CL; Bonini-Domingos CR
J Hum Genet; 2016 Jul; 61(7):605-11. PubMed ID: 26961071
[TBL] [Abstract][Full Text] [Related]
5. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
6. Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.
Silva DG; Belini Junior E; Carrocini GC; Torres Lde S; Ricci Júnior O; Lobo CL; Bonini-Domingos CR; de Almeida EA
BMC Med Genet; 2013 Oct; 14():108. PubMed ID: 24106994
[TBL] [Abstract][Full Text] [Related]
7. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
8. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
Silva DG; Belini Junior E; Torres Lde S; Ricci Júnior O; Lobo Cde C; Bonini-Domingos CR; de Almeida EA
Blood Cells Mol Dis; 2011 Jun; 47(1):23-8. PubMed ID: 21489839
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
10. Beta-globin gene cluster haplotypes in sickle cell patients from southwest Iran.
Rahimi Z; Karimi M; Haghshenass M; Merat A
Am J Hematol; 2003 Nov; 74(3):156-60. PubMed ID: 14587041
[TBL] [Abstract][Full Text] [Related]
11. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
[TBL] [Abstract][Full Text] [Related]
12. Atypical beta(s) haplotypes are generated by diverse genetic mechanisms.
Zago MA; Silva WA; Dalle B; Gualandro S; Hutz MH; Lapoumeroulie C; Tavella MH; Araujo AG; Krieger JE; Elion J; Krishnamoorthy R
Am J Hematol; 2000 Feb; 63(2):79-84. PubMed ID: 10629573
[TBL] [Abstract][Full Text] [Related]
13. Sickle cell disease in the Kurdish population of northern Iraq.
Al-Allawi NA; Jalal SD; Nerwey FF; Al-Sayan GO; Al-Zebari SS; Alshingaly AA; Markous RD; Jubrael JM; Hamamy H
Hemoglobin; 2012; 36(4):333-42. PubMed ID: 22686351
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
15. β-globin gene cluster haplotypes in sickle cell patients from Panamá.
Rusanova I; Cossio G; Moreno B; Javier Perea F; De Borace RG; Perea M; Escames G; Acuña-Castroviejo D
Am J Hum Biol; 2011; 23(3):377-80. PubMed ID: 21387457
[TBL] [Abstract][Full Text] [Related]
16. Homozygous sickle cell disease in Uganda and Jamaica a comparison of Bantu and Benin haplotypes.
Ndugwa C; Higgs D; Fisher C; Hambleton I; Mason K; Serjeant BE; Serjeant GR
West Indian Med J; 2012 Oct; 61(7):684-91. PubMed ID: 23620965
[TBL] [Abstract][Full Text] [Related]
17. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of the β-globin gene cluster haplotypes in a Sudanese population with sickle cell anaemia.
Elderdery AY; Mills J; Mohamed BA; Cooper AJ; Mohammed AO; Eltieb N; Old J
Int J Lab Hematol; 2012 Jun; 34(3):262-6. PubMed ID: 22260316
[TBL] [Abstract][Full Text] [Related]
19. Restriction mapping of βS locus among Tunisian sickle-cell patients.
Imen M; Ikbel BM; Leila C; Fethi M; Amine Z; Mohamed B; Salem A
Am J Hum Biol; 2011; 23(6):815-9. PubMed ID: 21965081
[TBL] [Abstract][Full Text] [Related]
20. Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
Rodríguez A; Kouegnigan L; Ferster A; Cotton F; Duez P
Hemoglobin; 2012; 36(6):545-54. PubMed ID: 23094637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
